Oracle Night, HIMS Earnings, and a Packed Week Ahead
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Earnings in Focus
Oracle reports Q4 2026 results tonight after the close. The $609B cloud giant carries just 2.1% short interest. Bears are not positioned for a miss. Options markets are the primary bearish vehicle, with heavy activity clustering around the June 12 expiry. Tomorrow, Adobe and homebuilder Lennar both post quarterly numbers. Luxury retailer RH also reports Wednesday.
HIMS in the Crossfire
Hims & Hers Health reports earnings today — and the setup is extreme. Short interest stands at 29.6% of free float. Availability has fallen to zero. No shares remain to borrow. Options are the only short vehicle left. Puts are stacking through June 12 and June 18 expiries. This is one of the highest-conviction short positions in mid-cap healthcare right now.
Meta vs. NSO Group
Meta filed a new legal action against Israel's NSO Group. The company says NSO defied a court order and launched a fresh Pegasus-linked phishing campaign through WhatsApp. The case adds another layer of regulatory and reputational risk to the spyware sector.
Europe: BT Reports Wednesday
UK telecom BT Group posts full-year 2026 results on Wednesday. Cybersecurity firm NCC Group also reports the same day. Both are watched closely as UK tech and telecom names face pressure from elevated borrowing costs and soft consumer sentiment.
Short Interest Snapshot
Nuclear name NNE climbed to 27.7% short interest this week. CrowdStrike earned an analyst upgrade with a $712 consensus target. REITs Prologis and Federal Realty were downgraded as rate pressure lingers.
Stocks in this article
How this article was generated
- Generated
- 10 Jun 2026, 04:51
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowORTEX Alpha signalsORTEX Alpha signalsAnalyst consensus
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.